View in EDS

Emerging Biologic Therapies for the Treatment of Atopic Dermatitis

Saved in:
Bibliographic Details
Title: Emerging Biologic Therapies for the Treatment of Atopic Dermatitis
Authors: José Miguel Alvarenga, Thomas Bieber, Tiago Torres
Source: Drugs
Publisher Information: Springer Science and Business Media LLC, 2024.
Publication Year: 2024
Subject Terms: Biological Therapy, Biological Products, Interleukin-13, Thymic Stromal Lymphopoietin, Interleukins, Biological Products/therapeutic use [MeSH], Interleukin-13/immunology [MeSH], Humans [MeSH], Interleukins/antagonists, Biological Products/pharmacology [MeSH], Dermatitis, Atopic/immunology [MeSH], Review Article, Interleukin-13/antagonists, Biological Therapy/methods [MeSH], Cytokines/metabolism [MeSH], Antibodies, Bispecific/pharmacology [MeSH], Interleukin-4/metabolism [MeSH], Interleukin-4/immunology [MeSH], Interleukins/metabolism [MeSH], Antibodies, Bispecific/therapeutic use [MeSH], Cytokines/antagonists, Thymic Stromal Lymphopoietin [MeSH], Interleukin-4/antagonists, Dermatitis, Atopic/drug therapy [MeSH], Antibodies, Bispecific, Humans, Cytokines, Interleukin-4, Dermatitis, Atopic
Description: Atopic dermatitis (AD) is a prevalent inflammatory skin disease having a significant impact on patients' quality of life. Conventional treatments, including topical therapies and systemic immunosuppressants, often have limited efficacy and long-term safety concerns. Emerging biologic therapies target specific immune pathways implicated in AD pathogenesis, offering new therapeutic options in a disease known for its complex immune pathomechanisms. This review focuses on novel biologics under investigation, particularly those targeting specific immune pathways such as interleukin-4 (IL-4), IL-13, IL-22, IL-31, thymic stromal lymphopoietin (TSLP), and OX40-OX40L axis. Interleukin-4 and IL-13 inhibitors aim to reduce Th2-driven inflammation, while IL-22 inhibitors focus on restoring skin barrier function. Interleukin-31 inhibitors help alleviate pruritus, a major symptom in AD. OX40-OX40L pathway inhibitors can selectively suppress the activity of pathogenic T cells, without inducing significant immunosuppression. Bispecific antibodies targeting both IL-4 and IL-31 pathways are emerging as potential dual-action treatment for AD. Thymic stromal lymphopoietin inhibitors offer a novel strategy to control inflammation. While many of these therapies offer promising safety and efficacy profiles, long-term studies and real-world data are essential to confirm their lasting impact. This review highlights the potential of these emerging systemic therapies to continue transforming AD management and improve patient outcomes.
Document Type: Article
Other literature type
Language: English
ISSN: 1179-1950
0012-6667
DOI: 10.1007/s40265-024-02095-4
Access URL: https://pubmed.ncbi.nlm.nih.gov/39365406
https://repository.publisso.de/resource/frl:6502524
Rights: CC BY NC
URL: http://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (http://creativecommons.org/licenses/by-nc/4.0/) .
Accession Number: edsair.doi.dedup.....3e9fbda7665e3440a5c75a2dc10b5a31
Database: OpenAIRE
Description
Abstract:Atopic dermatitis (AD) is a prevalent inflammatory skin disease having a significant impact on patients' quality of life. Conventional treatments, including topical therapies and systemic immunosuppressants, often have limited efficacy and long-term safety concerns. Emerging biologic therapies target specific immune pathways implicated in AD pathogenesis, offering new therapeutic options in a disease known for its complex immune pathomechanisms. This review focuses on novel biologics under investigation, particularly those targeting specific immune pathways such as interleukin-4 (IL-4), IL-13, IL-22, IL-31, thymic stromal lymphopoietin (TSLP), and OX40-OX40L axis. Interleukin-4 and IL-13 inhibitors aim to reduce Th2-driven inflammation, while IL-22 inhibitors focus on restoring skin barrier function. Interleukin-31 inhibitors help alleviate pruritus, a major symptom in AD. OX40-OX40L pathway inhibitors can selectively suppress the activity of pathogenic T cells, without inducing significant immunosuppression. Bispecific antibodies targeting both IL-4 and IL-31 pathways are emerging as potential dual-action treatment for AD. Thymic stromal lymphopoietin inhibitors offer a novel strategy to control inflammation. While many of these therapies offer promising safety and efficacy profiles, long-term studies and real-world data are essential to confirm their lasting impact. This review highlights the potential of these emerging systemic therapies to continue transforming AD management and improve patient outcomes.
ISSN:11791950
00126667
DOI:10.1007/s40265-024-02095-4